Charles Schwab Investment Management Inc. Acquires 26,964 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Charles Schwab Investment Management Inc. lifted its stake in scPharmaceuticals Inc. (NASDAQ:SCPH) by 35.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,854 shares of the company’s stock after buying an additional 26,964 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.21% of scPharmaceuticals worth $364,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Johnson Financial Group LLC acquired a new position in scPharmaceuticals during the fourth quarter valued at approximately $302,000. Bank of New York Mellon Corp raised its holdings in shares of scPharmaceuticals by 8.8% during the 4th quarter. Bank of New York Mellon Corp now owns 75,174 shares of the company’s stock worth $266,000 after buying an additional 6,051 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of scPharmaceuticals by 59.2% during the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock worth $3,503,000 after buying an additional 367,970 shares during the last quarter. Rhumbline Advisers boosted its stake in scPharmaceuticals by 20.1% in the fourth quarter. Rhumbline Advisers now owns 42,554 shares of the company’s stock valued at $151,000 after buying an additional 7,112 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in scPharmaceuticals in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Maxim Group dropped their price target on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, March 20th.

scPharmaceuticals Stock Down 11.4 %

Shares of NASDAQ:SCPH opened at $2.33 on Wednesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. scPharmaceuticals Inc. has a 52-week low of $2.31 and a 52-week high of $5.65. The business’s 50 day simple moving average is $3.22 and its two-hundred day simple moving average is $3.67. The firm has a market cap of $117.16 million, a P/E ratio of -1.23 and a beta of 0.40.

scPharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.08 million. As a group, research analysts forecast that scPharmaceuticals Inc. will post -1.53 EPS for the current fiscal year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.